2023
DOI: 10.1182/bloodadvances.2022008893
|View full text |Cite
|
Sign up to set email alerts
|

HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALL

Abstract: Chimeric antigen-receptor (CAR)-associated hemophagocytic lymphohistiocytosis (HLH)-like toxicities involving hyperferritinemia, multi-organ dysfunction, coagulopathy, and/or hemophagocytosis are described as occurring in a subset of patients with cytokine release syndrome (CRS). Case series report poor outcomes for those with B-acute lymphoblastic leukemia (B-ALL) who develop HLH-like toxicities, although larger outcomes analyses of children and young adults (CAYA) with B-ALL who develop these toxicities foll… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 7 publications
(2 citation statements)
references
References 31 publications
0
2
0
Order By: Relevance
“…Risk factors that have been implicated in the development of IEC-HS include baseline disease burden, CAR T proliferation dynamics, immune resistance mechanisms, target antigen, CAR T cell construct, costimulatory domain, T cell selection, cell dose and patient characteristics (baseline inflammation, immune suppression, cytopenias, genetic predisposition). ( 45 , 118 , 119 , 125 , 126 ). While the underlying pathophysiology of IEC-HS remains to be fully elucidated, similarities to CRS have been observed.…”
Section: Immune Effector Cell-associated Hemophagocytic Lymphohistioc...mentioning
confidence: 99%
“…Risk factors that have been implicated in the development of IEC-HS include baseline disease burden, CAR T proliferation dynamics, immune resistance mechanisms, target antigen, CAR T cell construct, costimulatory domain, T cell selection, cell dose and patient characteristics (baseline inflammation, immune suppression, cytopenias, genetic predisposition). ( 45 , 118 , 119 , 125 , 126 ). While the underlying pathophysiology of IEC-HS remains to be fully elucidated, similarities to CRS have been observed.…”
Section: Immune Effector Cell-associated Hemophagocytic Lymphohistioc...mentioning
confidence: 99%
“…As HLH-like toxicities independently predict poor survival, for instance after tisagenlecleucel, 1,17 effective treatment is urgently needed. Since guidance regarding the most appropriate second-and third-line agents is lacking, and systematic study may not be feasible, these cases highlight 3 different approaches for the treatment of IEC-HS.…”
Section: Case 3: Use Of Low-dose Etoposidementioning
confidence: 99%